Dongbu Signs 98.9 Billion KRW Contract Amendment with Royal Canin Korea for Pet Food Plant Construction, Boosting Revenue Outlook

Dongbu has entered into a contract amendment with Royal Canin Korea Limited for the construction of a pet food manufacturing facility, valued at 98,941,700,000 KRW. This represents an increase of approximately 34.9 billion KRW from the initial contract and accounts for 5.86% of Dongbu's 2024 consolidated revenue.
The contract period has been extended to August 31, 2026, though the amount and duration may change per contract conditions. This contract is expected to contribute to revenue growth in Dongbu's construction segment.
There is no capital change or share issuance, so no dilution risk for existing shareholders. The counterparty Royal Canin Korea, a subsidiary of global tier-1 company Mars, ensures a reliable revenue stream.
[AI Summary]Dongbu's large-scale contract win with Royal Canin positively impacts revenue growth without capital dilution, generating stable cash flows. The credible counterparty minimizes governance risk, making this favorable for shareholder value.